Wirtschaftsnachrichten (Symbolbild)
Donnerstag, 19.10.2023 16:05 von | Aufrufe: 110

Azenta to Host GENEWIZ Week November 6-10, 2023

Wirtschaftsnachrichten (Symbolbild) ©unsplash.com

PR Newswire

BURLINGTON, Mass., Oct. 19, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences will be hosting GENEWIZ Week November 6-10, 2023. The weeklong event will feature various virtual educational workshops, exclusive promotions, and a special grant program to recognize excellence in genomics research.

Throughout the course of the week, the experts in areas including next generation sequencing (NGS), PCR technologies and gene synthesis (GS) will be uncovering the many ways genomics is shaping workflows to go from sample-to-insights and from synthetic design to biological constructs. Each virtual workshop will be followed by an interactive roundtable with Azenta experts and guest speakers.

Each day of GENEWIZ Week will feature a different workshop topic. Online registration is now open.

Date

Time

Workshop Topic

Monday, November 6


ARIVA.DE Börsen-Geflüster

Kurse

52,64 $
+0,19%
Azenta Chart

10am & 3pm EST  

"Using Sanger to Complement ONT Whole Plasmid
Sequencing"

Tuesday, November 7

10am & 3pm EST  

"Antibody Sequencing to Synthesis: An Innovative Workflow
Leveraging Machine Learning to Prioritize Leads"

Wednesday, November 8   

10am & 3pm EST  

"Unlocking Lentivirus Potential: Benefits, Challenges &
Production"

Thursday, November 9

10am & 3pm EST  

"How Does it All Add Up? Quantitative PCR (qPCR) vs.
Digital PCR (dPCR)"

Friday, November 10

10am & 3pm EST  

"RNA-Seq Bioinformatics
Workshop"

During GENEWIZ Week, the company will recognize excellence in genomics research through its grant program totaling over $40,000 in credits, including a $20,000 grant towards a Proteomics Olink project. This year, seven winners will be awarded a grant for use towards a GENEWIZ service, as well as a bonus grant for consumables. Abstract submissions are due by November 3, 2023 for consideration, and winners will be announced after GENEWIZ Week concludes.

"We are thrilled to bring back our annual GENEWIZ Week," stated Ginger Zhou, SVP & General Manager, GENEWIZ Multiomics and Synthesis Solutions. "This event is a highlight for the team, and we look forward to a week full of collaboration and opportunities to engage with our customers."

Visit the website, GENEWIZ Week, for more details as well as the most up-to-date information.

About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:
Sara Silverman
Head of Investor Relations & Corporate Communications
ir@azenta.com

Sherry Dinsmore
sherry.dinsmore@azenta.com

Azenta logo (PRNewsfoto/Azenta)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-to-host-genewiz-week-november-6-10-2023-301962576.html

SOURCE Azenta

Werbung

Mehr Nachrichten zur Azenta Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News